StoryFunding
Colossal reportedly in talks to raise at a $20B-$30B valuation
Colossal Biosciences was reported to be in talks to raise money at a $20 billion to $30 billion valuation, two to three times the $10.2 billion it was valued at in January 2025. The company has started earning revenue through conservation technology, spinoff companies and biodiversity credits, and has raised roughly $615 million total capital, though the lead investor and round size for the current fundraising were not disclosed.
- $20B–$30B target valuation represents 2–3x increase from January 2025 ($10.2B valuation)
- Company started generating revenue in prior year through conservation tech and spinoff equity (Form Bio, Astromech at $2B)
- Total capital raised now ~$615M including new and previous rounds
- Colossal declined to comment on round specifics; investors not yet named